In a remarkable turn of events that underscores the volatility and potential of biotech investments, Merus stock has seen its stock soar by an impressive 36.12%. This surge is attributed to the promising outcomes of its latest cancer drug trials, igniting a wave of optimism among investors and stakeholders within the pharmaceutical sector. These results not only highlight … Continue reading Merus Stock Jumps 36.12% on Positive Cancer Drug Trial Outcomes